Wehi 164 Cell Model
Wehi 164 Cell Model - Related Videos
16:07
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
0 Views •
Cited by 1 •
2017
A protocol for the determination of the relative anti-apoptotic activity of an anti-TNFα mAb using a neutralization mechanism with WEHI 164 cells is presented here. This protocol is useful for comparing the neutralization strength of different molecules with the same biological functionality.
22:49
Optimized Staining and Proliferation Modeling Methods for Cell Division Monitoring using Cell Tracking Dyes
0 Views •
Cited by 45 •
2012
Successful use of cell tracking dyes to monitor immune cell function and proliferation involves several critical steps. We describe methods for: 1) obtaining bright, uniform, reproducible label-ing with membrane dyes; 2) selecting fluorochromes and data acquisition conditions; and 3) choosing a model to quantify cell proliferation based on dye dilution.
12:31
In Vivo Modeling of the Morbid Human Genome using Danio rerio
0 Views •
Cited by 66 •
2013
Here, we present a systematic approach for developing physiologically relevant, sensitive and specific in vivo assays for interpreting variation in human pathology. Transient genetic manipulation via microinjection of WT and mutant human mRNA and morpholino (MO) antisense oligonucleotides harness the tractability of the developing zebrafish embryo to rapidly assay pathogenic mutations, especially, but not exclusively, in the context of human developmental disorders.
03:06
Developing a Humanized Mouse Model with Human Liver Cells and Immune Cells
0 Views •
2025
This video demonstrates a method for generating a dual humanized mouse model with a human immune system and liver cells. It involves transplanting human liver cells and hematopoietic stem and progenitor cells into a transgenic immunodeficient mouse via intrasplenic injection, leading to engraftment of liver cells and development of human immune cells.
07:48
Organotypic Hippocampal Slice Cultures As a Model to Study Neuroprotection and Invasiveness of Tumor Cells
0 Views •
Cited by 18 •
2017
Organotypic hippocampal slice cultures (OHSC) represent an in vitro model that simulates the in vivo situation very well. Here we describe a vibratome-based improved slicing protocol to obtain high quality slices for use in assessing the neuroprotective potential of novel substances or the biological behavior of tumor cells.
FAQs
TNF or another test agent is applied to the cells, and the resulting change in metabolic activity or viability provides the primary readout. A reduction in that readout indicates growth inhibition or cell death. This links treatment exposure to a quantifiable biological response, allowing investigators to evaluate cytokine activity and compare the strength of cytotoxic effects.
Assay conditions influence how strongly WEHI 164 cells respond to an experimental treatment. Researchers can adjust these conditions to alter cellular sensitivity, which changes the magnitude of the measured viability or metabolic response. Controlling this variable is important when comparing agents, because differences in sensitivity can affect the apparent level of growth inhibition or cytotoxicity.
The model supports studies of cytokine activity, apoptosis, inflammatory signaling, and anticancer treatments. Its response to TNF or other agents provides an experimental basis for examining whether a treatment is associated with reduced cellular activity or viability. In medicine-focused research, these observations help connect inflammatory or cytokine-related mechanisms with potential effects on tumor cells.
Researchers expose comparable WEHI 164 cell assays to TNF and other candidate agents, then examine changes in metabolic activity or cell viability. The resulting responses provide a basis for comparing growth inhibition or cytotoxic effects under the selected conditions. This approach can show whether an agent produces a response similar to, weaker than, or stronger than the reference treatment.
A typical assay begins by exposing WEHI 164 cells to TNF or another experimental agent. After treatment, investigators assess metabolic activity or cell viability and use any reduction as evidence of growth inhibition or cell death. Conditions may then be adjusted to modify cellular sensitivity, enabling systematic evaluation of treatment effects and comparison among experimental groups.
Researchers can use the model to evaluate cytokine-mediated effects, investigate tumor-cell responses, and test candidate anticancer treatments in vitro. Because the system offers a reproducible way to compare cellular responses, it can be applied before further preclinical studies. Its results help prioritize compounds or mechanisms for subsequent investigation without replacing later-stage evaluation.
Reduced metabolic activity serves as an indicator that the treatment has decreased cellular viability or inhibited cell growth. The readout therefore provides evidence of a cytotoxic or growth-suppressive effect, although the overview associates the result with either growth inhibition or cell death. Researchers can use the measurement to compare responses across treatments and assay conditions.